World Cancer Day : IRE ELiT wants to encourage the research and development of radiopharmaceuticals applications for cancer imaging

IRE ELiT, one of the two worlds producers of Gallium-68 (Ga-68) radiopharmaceutical generators, is expanding its range with a Ga-68 generator specifically designed for preclinical research of new radiopharmaceuticals. At the preclinical stage, Ga-68 generators are mainly used in oncology for PET (positron emission tomography) diagnostic imaging to determine the number and aggressiveness of tumors and metastases.

Today, radiopharmaceuticals combining a Ga-68-labelled carrier molecule are already approved and many others are in the final stages of development. Access to Ga-68 generators has fundamentally changed the management of patients suffering from neuroendocrine cancers, which are particularly difficult to detect at an early stage. The results of ongoing clinical studies give the same hope for patients with recurrent prostate cancer, thanks to more precise diagnoses.

To encourage the research and development of other radiopharmaceuticals, IRE ELiT now offers to all research players, such as hospitals, university laboratories, research centers and healthcare manufacturers, a research generator dedicated to preclinical activities, i.e. the early stages of development before human clinical trials. This generator has the same level of quality and reliability as the generator authorized for clinical activities. However, in order to meet the needs of research teams, it will offer activities lower than those required for routine examinations at more accessible prices.

IRE ELiT's line of generators is therefore expanding, since Galli RD is being added to the radiopharmaceutical generators approved in Europe and in the US, as well as the Galli Demo, a demonstration model with no activity for team training. Galli RD is rapidly available to users - within a maximum of 8 weeks - thanks to an increase in IRE ELiT's production capacity to meet the needs of the market.

IRE ELiT's Strategic Director, Jean Bonnet, said "We want to make our contribution throughout the life cycle of radiopharmaceutical products, from their discovery to clinical application, by facilitating access to Ga-68 for research teams, which testify IRE ELiT's commitment to researchers and clinicians".

Bérénice Pignol

IRE - IRE ELiT

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About IRE and IRE ELiT

50 years dedicated to excellence in nuclear medicine

The IRE or the National Institute for Radioelements is a public utility foundation, whose main activity is the production of radioisotopes for diagnostic and therapeutic applications in the field of nuclear medicine. The IRE is the world leader in the production of molybdenum-99, the "parent" isotope of metastable technetium-99, and the most widely used in nuclear medicine for many examinations (heart, bone, lungs, thyroid, brain, kidneys, etc).


In addition to its production activities, the IRE contributes to protection and environmental monitoring through its services of measuring radioactivity in various samples, radiological characterisation of waste and contaminated elements and consultancy and technical assistance in the fields of radiology and nuclear energy.


For its part, IRE ELiT is IRE's innovation subsidiary founded in 2010 to develop radiopharmaceuticals used for imaging and treatment of certain cancers and palliative care. In 2020, the group devoted 15% of its turnover to R&D, a percentage which has been steadily increasing since the company's creation. IRE and IRE ELiT currently employ 250 people.

Contact

www.ire.eu